Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
about
The Recent Review of the Genitourinary Syndrome of MenopauseClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyAdvances in pharmacotherapy for treating female sexual dysfunction.Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopauseThe clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyAn update on drugs for the treatment of menopausal symptoms.Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors.The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women.Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women.Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophyVulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.Comparison between vaginal royal jelly and vaginal estrogen effects on quality of life and vaginal atrophy in postmenopausal women: a clinical trial study.The Impact of Inflammatory and Infectious Diseases of Vulvar on Quality of LifeRole of Vitamin D in urogenital health of geriatric participants.Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society.Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.Monurelle Biogel(®) vaginal gel in the treatment of vaginal dryness in postmenopausal women.Genitourinary syndrome of the menopause--dawn of a new era?Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.Medical and patient attitude towards vaginal atrophy: the AGATA study.The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey.CLarifying vaginal atrophy's impact On SEx and Relationships (CLOSER) survey in South Africa.A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.Vulvovaginal atrophy--a tale of neglect.Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.A Dermatologist's Approach to Genitourinary Syndrome of Menopause.
P2860
Q26781733-1B244CD2-B754-4ACA-80BA-641617EA6CD7Q28066699-1A95D627-955D-4F9F-B258-BCC614277A6CQ34465301-5E38EE2A-83FD-4FFB-B8C9-6D55EC8CF684Q34532021-AFAC23DC-F3BA-4366-BDD8-F2011712EC47Q35626394-14F04C65-AF06-4422-8171-399924490272Q35784054-C13D3DFB-FB25-465F-A436-97E06BC67F22Q36015161-E32EE79C-24F8-41FB-B57B-F6D58EFF6E70Q36112290-D4835B9E-BEB2-452B-ADFD-50EAF3835036Q36301955-28248D78-1F5A-47EE-AA0C-DEDD85F63E18Q36371627-71993B8F-7631-44F4-BA87-F51F5CC87312Q36482360-DEF51FF7-0259-4CE0-A75F-82C8F3D10476Q36762551-EF44F911-30C9-412F-96F3-247428E9D5AEQ37494813-AA1FFE85-22AF-4CA9-BE10-4492731600E1Q37567415-F58F1E3D-A0C6-454A-BACF-F61821D6B1F9Q37600020-F3B58C95-53C7-410B-886F-0E4EB1A3421BQ37721927-D93804D9-40E9-42DA-8CFD-8CC96EEF4511Q38242862-F00494CA-A4CD-4ABF-90C0-181D6B88B30EQ38254653-37F454B3-6C14-4247-8C4C-CD994831737BQ38374840-47C21E74-61A0-4D04-A0D8-72308E01A70EQ38586314-27F9D887-8D0F-4062-9DEF-CA59B4B1CB65Q38836000-441BB249-0C1F-4A17-A7B7-E99DDC8CD426Q38935535-29A98D77-DB17-4046-99A7-11AB8B3CB146Q39161528-76578F41-332C-4F8C-B2FA-3326373B706AQ39161834-A8CFF7FB-318F-4A9B-B597-7B99EC757D9AQ39295958-98C58F0B-FAEF-4036-BDF6-66FBC67C83F4Q45951188-3329875D-75F0-4B28-B983-26236059CA19Q46728259-955510D8-EB90-4C5F-B005-D761775A1173Q47422709-2D34FD70-61C9-4779-BA4A-061F1C37E23EQ48097089-C9DA0236-ED5E-4A7A-9DD4-9F953D68430FQ50964914-AD579783-9497-40DA-93B3-95BCB1C3621CQ52929113-47FEEAF9-87A5-4965-B0FF-E3CD6A18120AQ53325328-12A64738-A504-482A-93D1-EFE919968CF3
P2860
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
@en
type
label
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
@en
prefLabel
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
@en
P2860
P1433
P1476
Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
@en
P2093
P2860
P356
10.3109/13697137.2013.871696
P577
2014-02-01T00:00:00Z